(NASDAQ: BSEM) Biostem Technologies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Biostem Technologies's revenue in 2026 is N/A.On average, 3 Wall Street analysts forecast BSEM's revenue for 2026 to be $523,185,844, with the lowest BSEM revenue forecast at $502,658,953, and the highest BSEM revenue forecast at $538,572,088. On average, 3 Wall Street analysts forecast BSEM's revenue for 2027 to be $981,935,099, with the lowest BSEM revenue forecast at $943,415,940, and the highest BSEM revenue forecast at $1,010,815,543.
In 2028, BSEM is forecast to generate $1,543,390,209 in revenue, with the lowest revenue forecast at $1,482,880,502 and the highest revenue forecast at $1,588,799,263.